GlaxoSmithKline plc
News and overview for GlaxoSmithKline plc
SuperGen, GlaxoSmithKline sign collaboration deal - MarketWatch
MarketWatch | 27 days 14 hours 12 minutes ago
HSBC Holdings to sell some HSS France ops
FDA approves GlaxoSmithKline renal cancer drug - MarketWatch
MarketWatch | 33 days 23 hours 14 minutes ago
GSK
Reportlinker Adds GlaxoSmithKline plc: PharmaVitae Profile [Press Release]
PRNewswire | 19 days 2 hours 26 minutes ago
...reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile...2002-14 59 Figure 16: GlaxoSmithKline prescription pharmaceutical...reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile...
FDA warns against taking Plavix with Prilosec - MarketWatch
MarketWatch | 5 days 5 hours 59 minutes ago
Prilosec, also known as omeprazole or Losec, is marketed by AstraZeneca plc /quotes/comstock/13*!azn/quotes/nls/azn (AZN 45.23, -0.97, -2.10%) .
Zacks Analyst Blog Highlights: GlaxoSmithKline plc, Sanofi-Aventis, Novartis, Baxter International and AstraZeneca [Press Release]
Business Wire | 6 days 2 hours 26 minutes ago
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: GlaxoSmithKline plc (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), Novartis (NYSE: NVS), Baxter International (NYSE: BAX) and AstraZeneca (NYSE: AZN).
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus [Press Release]
Business Wire | 20 days 12 hours 26 minutes ago
Human Genome Sciences, Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with place...
Vivus reports postive study results for ED drug - MarketWatch
MarketWatch | 4 days 9 hours 39 minutes ago
Drug stocks mixed; Vivus jumps on study
Nabi, Glaxo agree nicotine vaccine licensing deal - MarketWatch
MarketWatch | 6 days 13 hours 8 minutes ago
Nabi, Glaxo agree nicotine vaccine licensing deal
Drug stocks move lower; Vivus, Poniard gain - MarketWatch
MarketWatch | 4 days 8 hours 47 minutes ago
Shares of Vivus /quotes/comstock/15*!vvus/quotes/nls/vvus (VVUS 8.99, +0.42, +4.90%) climbed 9% to $9.31.
Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis [Press Release]
Business Wire | 4 days 9 hours 25 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/ff5934/antibiotics_glob) has announced the addition of the "Antibiotics - Global Trends" report to their offering.
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus [Press Release]
MarketWire | 20 days 13 hours 25 minutes ago
ROCKVILLE, MD and LONDON -- (Marketwire) -- 11/02/09 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that
Research and Markets: Alzheimer's and Parkinson's Diseases - a Global Update of Market Trends & Opportunities [Press Release]
Business Wire | 3 days 11 hours 26 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/5f3158/alzheimers_and_pa) has announced the addition of the "Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities" report to their offering.
Research and Markets: Anti-Aging Products - a Global Update of Market Trends & Opportunities [Press Release]
Business Wire | 3 days 9 hours 26 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/64e5c4/antiaging_product) has announced the addition of the "Anti-Aging Products - A Global Update of Market Trends & Opportunities" report to their offering.
Human Genome, GSK see progress with lupus drug - MarketWatch
MarketWatch | 20 days 17 hours 38 minutes ago
Human Genome, GSK see progress with lupus drug
Tuesday's biggest gaining and declining stocks - MarketWatch
MarketWatch | 33 days 13 hours 6 minutes ago
Investors might be getting a bit ahead of themselves when it comes to shares of Apple Inc.
Sign up for AANP SmartBrief
Company Overview
| Company: | GlaxoSmithKline plc |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.gsk.com |
GlaxoSmithKline (GSK) calms your nerves and helps you breathe easier. One of the top five pharmaceutical firms in the world, GSK's top sellers include central nervous system therapies, respiratory drugs, and antiviral therapies, as well as vaccines. The company's top product is asthma medication Advair, which combines two of the company's other products, Flovent and Serevent. Other bestsellers include herpes treatment Valtrex, epilepsy treatment Lamictal, antidepressant Paxil, migraine therapy Imitrex, and antibiotic Augmentin. The company's consumer products include Tums for sour stomachs, dental care products Aquafresh and Sensodyne, and smoking-cessation products NicoDerm and Nicorette.
Key Numbers
| Sales in U.S. Dollars (mil.) | 35,244.602 (2008) |
|---|---|
| One-year % Growth in Sales | -22.3 (2008) |
| Net Income in U.S. Dollars (mil.) | 6,819.7 (2008) |
| One-year % Growth in Net Income | -34.5 (2008) |
| Number of Employees | 99,003 (2008) |
| One-year % Growth in Number of Employees | -3.9 (2008) |
| Fiscal Year-End | December |